Latest Breaking News On - பணி உயிர் இன்க் - Page 1 : comparemela.com

Executive Profile: Yan Zhang, CEO, Mission Bio Inc - San Francisco Business Times

Executive Profile: Yan Zhang, CEO, Mission Bio Inc - San Francisco Business Times
bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.

Yan zhangUnited statesSan franciscoRon leutyMission bioMission bio incStaff reporterSan francisco business timesThermo fisher scientificApril whatயான் ஜாங்ஒன்றுபட்டது மாநிலங்களில்சான் பிரான்சிஸ்கோபணி உயிர்பணி உயிர் இன்க்ஊழியர்கள் நிருபர்

Global MRD (Minimal Residual Disease) Testing Markets 2020-2025: Opportunities in Potential Long-Term Cost Savings & Technological Evolution of Testing

Share this article Share this article ResearchAndMarkets.com s offering. The global market for MRD testing is predicted to grow at a CAGR of 15.64% over the forecast period, 2020-2025. MRD Testing industry to be one of the most rapidly evolving and dynamic markets. The market is driven by certain factors, such as the rising incidence of hematologic malignancies, the increasing consumer awareness for tailored therapy, the increasing research funding from the National Cancer Institute, and the increasing disposable income in emerging economies. The market is favored by the developments in the field of MRD testing solutions for hematologic malignancies and solid tumors. Currently, the MRD testing industry is witnessing an upsurge due to the rising incidence of hematologic malignancies, resulting in the high demand for sensitive testing solutions. Additionally, the high adoption of MRD tests among patients and the growing awareness among physicians regarding MRD testing are some o

United statesLaura woodNatera incGuardant healthQuest diagnostics incorporatedNational cancer instituteAdaptive biotechnologies corporationLaboratory developed tests ldtsSysmex corporationPart of invitae corporationConsiderations for cellular technology platformsInivata ltdOpko health incConsiderations for molecular technology platformsInvivoscribe incCustom research

Global MRD (Minimal Residual Disease) Testing Market Report 2020-2025: One of the Most Rapidly Evolving and Dynamic Markets

Global MRD (Minimal Residual Disease) Testing Market Report 2020-2025: One of the Most Rapidly Evolving and Dynamic Markets January 22, 2021 07:18 ET | Source: Research and Markets Research and Markets Dublin, IRELAND ResearchAndMarkets.com s offering. The global market for MRD testing is predicted to grow at a CAGR of 15.64% over the forecast period, 2020-2025. MRD Testing industry to be one of the most rapidly evolving and dynamic markets. The market is driven by certain factors, such as the rising incidence of hematologic malignancies, the increasing consumer awareness for tailored therapy, the increasing research funding from the National Cancer Institute, and the increasing disposable income in emerging economies.

United statesLaura woodNatera incGuardant healthQuest diagnostics incorporatedNational cancer instituteAdaptive biotechnologies corporationLaboratory developed tests ldtsSysmex corporationPart of invitae corporationConsiderations for cellular technology platformsInivata ltdOpko health incConsiderations for molecular technology platformsInvivoscribe incCustom research

BIS Research Study Highlights the Global MRD Market to Reach $1 61 Billion by 2025

Share this article Share this article FREMONT, Calif., Jan. 13, 2021 /PRNewswire/ The premium market intelligence report published by BIS Research on the title Global MRD Testing Market highlights that the market is projected to reach $1.61 billion by 2025. The study also highlights that the market is set to witness a CAGR of 15.64% during the period between 2020 and 2025. The growth is aided by factors including increasing research funding from the National Cancer Institute and rising incidence of hematologic malignancies, among others. Minimal residual disease (MRD) testing is an evolving testing regimen that has been driving initiatives in the management of hematological malignancy patients. It is currently one of the fastest-growing markets under the molecular diagnostics umbrella. MRD testing promises the integration of evolutionary molecular technologies into hematological malignancy care regimens, thereby driving tremendous growth in the overall hematological malignanc

United statesBhavya bangaNitish kumar singhNatera incGuardant healthQuest diagnostics incorporatedNational cancer instituteInsightful questions covered to enable companiesSysmex corporationTechnology flow cytometryDigital healthInivata ltdInformation technologyResearch incOpko health incInvivoscribe inc